These ASH 2020 guidelines present 28 GRADE-based recommendations for treating DVT and PE in non-cancer adults. They cover anticoagulant selection, treatment duration, secondary prevention, and management of recurrent events. The panel used systematic evidence review across 12 major RCTs and multiple meta-analyses to generate actionable clinical guidance.
Every post-op orthopedic patient who develops DVT or PE lands you squarely inside these guidelines. The key decisions you will face map directly to the three treatment phases ASH defines: initial management (home vs. Hospital, anticoagulant choice), primary treatment (how long), and secondary prevention (stop or continue).
When your patient has a new DVT or PE and no contraindications, start a DOAC — not warfarin. The major bleeding reduction is high-certainty and clinically meaningful. If the patient has CrCl <30, significant liver disease, or antiphospholipid syndrome, VKA is the appropriate fallback.
When PE presents with hemodynamic compromise (hypotension, shock), give thrombolytics. This is one of the few strong GRADE recommendations in the guidelines, and it holds even though the underlying evidence is low-certainty. The mortality stakes justify the bleeding risk. Submassive PE (RV strain without hypotension) does not meet this bar; anticoagulate and watch closely.
Plan 3–6 months of primary anticoagulation for any VTE. A post-op DVT provoked by surgery (transient risk factor) typically stops there. An unprovoked DVT. Especially if recurrent. Warrants indefinite therapy. If VKA is used for secondary prevention, target INR 2.0–3.0, not a lower range.
These ASH 2020 guidelines present 28 GRADE-based recommendations for treating DVT and PE in non-cancer adults. They cover anticoagulant selection, treatment duration, secondary prevention, and management of recurrent events. The panel used systematic evidence review across 12 major RCTs and multiple meta-analyses to generate actionable clinical guidance.
Every post-op orthopedic patient who develops DVT or PE lands you squarely inside these guidelines. The key decisions you will face map directly to the three treatment phases ASH defines: initial management (home vs. Hospital, anticoagulant choice), primary treatment (how long), and secondary prevention (stop or continue).
When your patient has a new DVT or PE and no contraindications, start a DOAC — not warfarin. The major bleeding reduction is high-certainty and clinically meaningful. If the patient has CrCl <30, significant liver disease, or antiphospholipid syndrome, VKA is the appropriate fallback.
When PE presents with hemodynamic compromise (hypotension, shock), give thrombolytics. This is one of the few strong GRADE recommendations in the guidelines, and it holds even though the underlying evidence is low-certainty. The mortality stakes justify the bleeding risk. Submassive PE (RV strain without hypotension) does not meet this bar; anticoagulate and watch closely.
Plan 3–6 months of primary anticoagulation for any VTE. A post-op DVT provoked by surgery (transient risk factor) typically stops there. An unprovoked DVT. Especially if recurrent. Warrants indefinite therapy. If VKA is used for secondary prevention, target INR 2.0–3.0, not a lower range.